Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.S*BIO, an oncology-focused biotech company, has noticed positive safety, tolerability and pharmacokinetic/pharmacodynamic (PK/PD) results for the Phase 1/2 dose-escalation trial of its oral JAK2 inhibitor, SB1518 for the Treatment of Myelofibrosis (MF).
Subscribe to our email newsletter
The findings were presented at the 15th Congress of the European Hematology Association (EHA), June 10-13, in Barcelona, Spain.
According to the S*BIO 20 patients were treated at multiple dose levels ranging between 100 mg to 600 mg once daily. Clinical improvements were observed in hemoglobin, platelet and splenomegaly categories. The dose-limiting toxicities were gastrointestinal related and were only seen at the 600 mg dose level.
The clinical study was conducted at Peter MacCallum Cancer Center, Royal Melbourne Hospital, and Royal Adelaide Hospital, in Australia.
Jan-Anders Karlsson, CEO of S*BIO, said: “The clinical findings demonstrate SB1518’s potential as a viable treatment for myelofibrosis. These results are consistent with the data presented at the ASH Annual Meeting in 2009 from our US Phase 1 trials in which safety, tolerability and signs of activity in different disease states had been observed.
“The positive findings allowed us to advance rapidly our clinical program and complete enrollment of the Phase 2 myelofibrosis trials for SB1518 to test further the safety and efficacy of our compound.”